Results 31 to 40 of about 2,835 (182)

Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects

Clinical and Translational Science, 2022
Filgotinib, a preferential Janus Kinase‐1 inhibitor, is approved in Europe and Japan for treatment of rheumatoid arthritis and is being developed for treatment of other chronic inflammatory diseases. Three drug‐drug interactions studies were conducted in
Chia‐Hsiang Hsueh, Kacey Anderson, Gong Shen, Chohee Yun, Ann Qin, Ahmed A. Othman   +5 more
doaj   +1 more source

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial [PDF]

, 2021
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-alpha inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with ...
Ye, L., Guo, Ying, Genovese, M.C., Matzkies, Franziska, Simon, J.A., Simon, J. Abraham, Landewe, R.B.M., Ye, Lei, Keystone, Edward, Keystone, Edward C, Baraf, Herbert S. B., Genovese, Mark C., Landewé, Robert, van Der Heijde, Désirée, Kivitz, Alan, Combe, Bernard, Landewé, Robert BM, Bae, Sang-Cheol, van der Heijde, D. sirée, Matzkies, F., Tasset, C., Keystone, Edward C., Sundy, J.S., Heijde, D. van der, Guo, Y., Tanaka, Y., Tasset, Chantal, Mozaffarian, Neelufar, Baraf, Herbert, Sundy, John, Bartok, Beatrix, Bartok, B., Baraf, Herbert SB, Mozaffarian, N., Kumar, Uma, Sundy, John S., Tanaka, Yoshiya, Baraf, H.S.B., Sundy, John S, Nash, P., Jahreis, Angelika, Kumar, U., Jahreis, A., Genovese, Mark, Bae, S.C., Genovese, Mark C, Nash, Peter, Keystone, E.C., Simon, J Abraham, Kivitz, A., Combe, B., Landewé, Robert B. M.   +51 more
core   +1 more source

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial [PDF]

Intestinal Research, 2023
Background/Aims The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial.
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Brian G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, Akira Kondo, Mamoru Watanabe   +15 more
doaj   +1 more source

Filgotinib: A Clinical Pharmacology Review

Clinical Pharmacokinetics, 2022
Filgotinib (GS-6034, formerly GLPG0634; Jyseleca®) is an oral, preferential Janus kinase (JAK)-1 inhibitor. Preferential inhibition of JAK1 modulates a subset of proinflammatory cytokines within the JAK-signal transducer and activator of transcription pathway, which differ from those inhibited by JAK2 or JAK3.
Florence Namour, Kacey Anderson, Cara Nelson, Chantal Tasset   +3 more
openaire   +2 more sources

Filgotinib in Rheumatoid Arthritis: A Profile of Its Use [PDF]

Clinical Drug Investigation, 2021
Filgotinib (Jyseleca®), an oral Janus kinase (JAK) inhibitor, is approved as monotherapy or in combination with methotrexate to treat moderate to severe active rheumatoid arthritis (RA) in adults who have an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).
Esther S. Kim, Susan J. Keam
openaire   +2 more sources

Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3

RMD Open, 2021
Objective This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with multiple poor prognostic factors (PPFs).Methods This was a ...
René Westhovens, Thijs Hendrikx, Beatrix Bartok, Cécile Gaujoux-Viala, Giovanni Adami, Zhaoyu Yin, Ying Guo, Osvaldo Daniel Messina, Alan Matsumoto   +8 more
doaj   +1 more source

Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis

Frontiers in Bioscience-Landmark, 2023
Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease that causes progressive joint damage. The Janus kinase (JAK) inhibitors (JAK-I) represent a new therapeutic option for RA patients, blocking the intracellular JAK-STAT pathway. Today,
Maurizio Benucci, Francesca Li Gobbi, Paola Fusi, Arianna Damiani, Edda Russo, Serena Guiducci, Mariangela Manfredi, Valentina Grossi, Maria Infantino, Amedeo Amedei   +9 more
doaj   +1 more source

Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).

, 2021
Objectives Evaluate the efficacy and safety of the Janus kinase-1 inhibitor filgotinib in Japanese patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX).
Bartok, Beatrix, Bae, Sang-Cheol, Matzkies, Franziska, Amano, Koichi, Matsubara, Tsukasa, Yamaoka, Kunihiro, Tanaka, Yoshiya, Nash, Peter, Ishiguro, Naoki, Pechonkina, Alena, Keystone, Edward C, Atsumi, Tatsuya, Sugiyama, Eiji, Kivitz, Alan J, Combe, Bernard G, et al.   +15 more
core   +1 more source

Filgotinib in Crohn’s Disease: JAK Is Back [PDF]

Gastroenterology, 2017
n ...
Danese, Silvio, Fiorino, Gionata, Peyrin-Biroulet, Laurent   +2 more
openaire   +3 more sources

Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post hoc Analysis of the Phase 2b/3 SELECTION Study [PDF]

, 2023
BACKGROUND AND AIMS: SELECTION is the first study to assess the impact of concomitant thiopurine and other immunomodulator [IM] use on the efficacy and safety of a Janus kinase inhibitor, filgotinib, in patients with ulcerative colitis.
Watanabe, Kenji; https://orcid.org/, Fujitani, Yasushi, Oortwijn, Alessandra, Lindsay, James O, Danese, Silvio; https://orcid.org/, Rogler, Gerhard; https://orcid.org/, Hibi, Toshifumi, Peyrin-Biroulet, Laurent, Faes, Margaux   +8 more
core   +3 more sources